AMRN - BIIB Is For Buy-O-Gen
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price.
The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sclerosis (MS), SPINRAZA for the treatment of spinal muscular atrophy (SMA), and a number of biosimilars. BIIB has a range of other products and drug candidates in various stages of development.
Financial Performance Remains Strong
First, some financial metrics are in order. Let's get grounded. Sentiment is volatile, numbers-based performance is not...
Source: